Evidence map›Paper›PMID 23825598›Full record

ArticlePloS one2013

A new in vivo screening paradigm to accelerate antimalarial drug discovery.

María Belén Jiménez-Díaz, Sara Viera, Javier Ibáñez, Teresa Mulet, Noemí Magán-Marchal, Helen Garuti, Vanessa Gómez, Lorena Cortés-Gil, Antonio Martínez, Santiago Ferrer and 9 more

Abstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Humanization of Drug Metabolism in theACS infectious diseases · 2025
    Article
  4. Article
  5. The Pan African medical journal · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Model-Informed Drug Development for Malaria Therapeutics.Annual review of pharmacology and toxicology · 2018
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

María Belén Jiménez-DíazTres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain.
Sara Viera
Javier Ibáñez
Teresa Mulet
Noemí Magán-Marchal
Helen Garuti
Vanessa Gómez
Lorena Cortés-Gil
Antonio Martínez
Santiago Ferrer
María Teresa Fraile
Félix Calderón
Esther Fernández
Leonard D Shultz
Didier Leroy
David M Wilson
José Francisco García-Bustos
Francisco Javier Gamo
Iñigo Angulo-Barturen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P0) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task.

Indexed as

AnimalsAntimalarialsDrug Evaluation, PreclinicalFeasibility StudiesFemaleHumansMalariaMiceParasitemiaPlasmodium bergheiTime FactorsAntimalarials

Identifiers

PMID23825598
PMCPMC3692522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.